Medplus Health Services Ltd Upgrades Quality Grade Amid Improving Fundamentals

Quality Grade Upgrade and Market Reaction

On 21 May 2026, Medplus Health Services Ltd’s quality grade was upgraded from below average to average, a move that has been well received by the market. The company’s Mojo Score, a comprehensive metric assessing financial health and growth prospects, increased to 71.0, prompting an upgrade in its Mojo Grade from Hold to Buy. This shift underscores the company’s improving fundamentals and growing investor confidence.

The stock price responded positively, closing at ₹954.65 on 22 May 2026, up 4.20% from the previous close of ₹916.15. Intraday, the stock touched a high of ₹1,020.35, nearing its 52-week high of ₹1,052.05, signalling strong buying interest. Over the past month, Medplus has outperformed the Sensex significantly, delivering an 8.62% return against the benchmark’s 5.16% decline, and a year-to-date return of 18.41% compared to Sensex’s negative 11.78%.

Improvement in Profitability Metrics

One of the key drivers behind the quality upgrade is the improvement in profitability ratios. Medplus’s average Return on Capital Employed (ROCE) stands at 6.52%, while its average Return on Equity (ROE) is 5.80%. Although these figures remain modest compared to industry leaders, they represent a stabilisation and slight improvement from previous years when the company struggled with subpar returns.

ROCE is a critical indicator of how efficiently a company utilises its capital to generate earnings before interest and tax. Medplus’s ROCE of 6.52% suggests that the company is beginning to generate better returns on its invested capital, a positive sign for long-term value creation. Similarly, the ROE of 5.80% indicates improved profitability for shareholders, albeit still below the ideal double-digit benchmark for retailing companies.

Consistent Growth in Sales and EBIT

Medplus has demonstrated consistent growth over the past five years, with a sales growth rate of 16.21% and an EBIT growth rate of 20.68%. These figures highlight the company’s ability to expand its top line and improve operating profitability simultaneously. The EBIT growth outpacing sales growth is particularly encouraging, signalling operational leverage and better cost management.

Such growth rates are commendable in the retailing sector, which faces intense competition and margin pressures. Medplus’s ability to sustain this growth trajectory while improving profitability metrics has been a key factor in its quality grade upgrade.

Debt Levels and Interest Coverage

Debt management remains a mixed aspect for Medplus. The company’s average Debt to EBITDA ratio is 3.08, indicating moderate leverage. While this level is not alarming, it suggests that the company carries a reasonable debt burden relative to its earnings before interest, tax, depreciation, and amortisation. The Net Debt to Equity ratio averages 0.45, reflecting a balanced capital structure with manageable debt levels.

However, the EBIT to Interest coverage ratio averages 1.93, which is on the lower side. This means that earnings before interest and tax cover interest expenses less than twice, signalling some vulnerability to interest rate fluctuations or earnings volatility. Investors should monitor this metric closely, as improving interest coverage would enhance financial stability and reduce refinancing risks.

Capital Efficiency and Taxation

Medplus’s Sales to Capital Employed ratio averages 1.93, indicating that the company generates nearly twice its capital employed in sales revenue. This level of capital turnover is reasonable for a retailing business, reflecting efficient utilisation of assets to drive sales. The company’s tax ratio stands at 20.24%, consistent with prevailing corporate tax rates, and does not raise any concerns regarding tax efficiency or liabilities.

Shareholding and Pledge Status

Institutional investors hold 43.35% of Medplus’s shares, a healthy level that provides stability and confidence in the company’s prospects. However, a significant 60.74% of shares are pledged, which is a potential red flag. High pledged shareholding can indicate promoter reliance on debt or liquidity constraints, which may pose risks if market conditions deteriorate or if the company’s performance falters.

Comparative Industry Positioning

Within the retailing sector, Medplus’s quality grade upgrade to average places it ahead of several peers such as Brainbees Solutions and Aditya Birla Fashion, which remain below average. It is on par with companies like V2 Retail and Arvind Fashions, while still trailing behind stronger performers like Vedant Fashions and Aditya Vision, which hold good quality grades.

This relative positioning suggests that while Medplus is making progress, there remains room for improvement to reach the upper echelons of retailing companies in terms of operational excellence and financial robustness.

Long-Term Returns and Investor Outlook

Medplus has delivered strong returns relative to the Sensex over multiple time frames. Over three years, the stock has returned 39.03%, significantly outperforming the Sensex’s 21.79%. Year-to-date, the stock’s 18.41% gain contrasts sharply with the Sensex’s 11.78% decline, highlighting Medplus’s resilience and growth potential amid broader market volatility.

These returns, combined with the recent quality grade upgrade and Buy rating, make Medplus an attractive proposition for investors seeking exposure to the retailing sector with improving fundamentals. However, investors should remain mindful of the company’s moderate profitability ratios and leverage metrics, which require ongoing monitoring.

Conclusion: A Balanced Improvement in Fundamentals

Medplus Health Services Ltd’s upgrade in quality grade from below average to average reflects a meaningful improvement in its business fundamentals. The company has demonstrated consistent sales and EBIT growth, improved capital efficiency, and a stabilising profitability profile. While debt levels remain moderate and interest coverage is somewhat constrained, the overall financial health is trending positively.

Investor sentiment has responded favourably, with the stock outperforming the benchmark indices and receiving a Buy rating supported by a strong Mojo Score. Going forward, further enhancements in return ratios and debt servicing capacity will be critical for Medplus to elevate its quality grade further and sustain its growth momentum in the competitive retailing landscape.

53% Discount is LIVE - Get MojoOne + Stock of the Week for 3 Years Start Today